GBM46 GBM Model

GBM46, a Patient-Derived Xenograft (PDX) model, offers valuable insights into brain cancer. Use this model to delve into disease mechanisms and develop innovative approaches to treatment. PDX models like GBM46 are crucial for preclinical drug discovery, allowing researchers to assess potential drug candidates in a controlled and representative tumor environment. GBM46 accelerates the identification of effective treatments and personalized therapies, offering hope to brain cancer patients.

Model Details

Cancer Location: Intracranial
Cancer Type: Brain Cancer
Model Name: GBM46
Mouse Strain: Nu/Nu
Treatment Data Available: Chemotherapy (Temozolomide), Radiation (2Gy)
WES: Yes
RNAseq: Yes
Methylation: Yes
EGFR Exon Varient: Del. exons 13-14
PDX Treatment: Yes
Patient Treatment History: Yes

GBM46 Survival

Survival of orthotopic intracranial implanted  GBM46 in Nu/Nu mice  (n=10)

Request Additional GBM Model Data

Contact Us

Get Started.

Have questions about how TD2 can assist with your regulatory needs? Reach out to our
expert staff today to get started.

Skip to content